Company Filing History:
Years Active: 2012
Title: Dan Strumpf: Innovator in Lung Cancer Prognostics
Introduction
Dan Strumpf is an accomplished inventor based in Toronto, Canada, recognized for his significant contributions to the field of oncology. His innovative work primarily revolves around developing methods to enhance patient prognosis for lung cancer, thus paving the way for improved treatment protocols.
Latest Patents
Dan holds a patent titled "Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy." This patent features a groundbreaking application that provides methods for prognosing and classifying lung cancer patients into distinct survival groups—poor survival and good survival. Moreover, it outlines ways to determine the efficacy of adjuvant chemotherapy through a multigene signature. The patent also incorporates kits and computer products designed for use with these novel methods, showcasing Dan's commitment to integrating technology with clinical practice.
Career Highlights
Dan Strumpf is associated with the University Health Network, where he leverages his expertise in gene analysis and cancer prognostics. His role at this prestigious institution underscores his dedication to advancing medical research and improving patient outcomes. His single patent exemplifies the impact he has made in the medical community, especially in the fight against lung cancer.
Collaborations
Throughout his career, Dan has collaborated with notable colleagues, including Ming-Sound Tsao and Frances A. Shepherd. These partnerships have played a crucial role in the development of his patented methods, fostering an environment of innovation and teamwork that aims to transform cancer treatment strategies.
Conclusion
In summary, Dan Strumpf stands out as a significant figure in cancer research, with his innovative approaches to lung cancer prognosis. His patent not only represents a milestone in scientific advancement but also signals hope for patients facing lung cancer. Through his work at the University Health Network and collaborations with fellow researchers, Dan continues to contribute to a brighter future in oncology.